Neurosteer has developed the world’s first medical-grade, real-time brain sensing and control, wearable platform for a wide range of medical, wellness and lifestyle applications.

Combining advanced neuroscience and proprietary machine learning, Neurosteer captures brain activity, interprets brain dynamics, and detects emotions, neurological states, engagement, attention and intent in real time.

It is an essential tool for monitoring patients with neurological disorders, and is used in the hospital, rehab center and at home.

The minimal, wearable sensor is the perfect digital companion for neurological and psychiatric clinical trials.



A sticker-size, sticker-thin sensor offers medical grade accuracy, using three EEG electrodes on the forehead and proprietary cloud-based software.  This provides unique biomarkers and alerts for cognitive load, emotional states, sleep and pain, abnormal (epileptic) activity, disorders of consciousness and
level of anesthesia.

Brain stimulation is used for repeated brain assessment and increased robustness.

The novelty of Neurosteer’s technology is based on flexible electronics combined with smart algorithms (Harmonic Analysis) which processes the EEG data in real-time, producing biomarkers which are easy to use and do not require EEG-expert interpretation.

The result is a much finer brain activity analysis than spectral multi-electrode EEG analysis — a groundbreaking tool for brain health management.



Neurosteer’s technology measures cognitive load, emotional response, stress and executive functions, as well as level of consciousness and anesthesia.

Clinical Trial Companion

Neurosteer provides the first ever miniature, easy-to-use and continuous neurological monitor. While improving medical intervention, this disruptive technology also provides neurological biomarkers. This helps pharmaceutical companies introduce new neurological and psychiatric drugs to the market, and streamline drug development and discovery. It enables better and less expensive patient screening and the continuous monitoring of patients throughout the study, addressing various compliance issues. It can accelerate “research-to-cure” time and improve patient condition characterization, leading to more personalized medicine, which will improve study accuracy and accelerate regulatory approval.

Continuous monitoring of minimally conscious and anesthetized patients

Patients who have lost consciousness due to brain trauma, or are sedated during surgery, or as part of treatment, may experience life threatening reactions that could further damage the brain. These include post trauma epilepsy, increased intracranial pressure, and repeated ischemic events. Continuous brain monitoring and real-time alerts are crucial to reducing secondary damage. In anesthesia, it is important to maintain sufficient unconsciousness to reduce pain, while maintaining the right balance to reduce potential damage.

 Disorders of Consciousness Companion

Patients  on the Disorders of Consciousness spectrum may experience episodes of greater responsiveness. Optimized intervention requires continuous assessment and characterization of the degree of responsiveness, and precision brain stimulation for maximal brain response. This improves intervention, as caregivers receive alerts about the degree of responsiveness following treatment. Real-time response indication allows therapists to understand the results of types and timing of stimulation, and adjust protocols accordingly.


Neurosteer at Stanford University

Neurosteer’s Nathan Intrator will discuss mobile brain sensing in clinical trials at the Neurotech conference at Stanford on February 26-27, 2018.  Other speakers include DARPA’s Justin Sanchez; Kernel’s Bryan Johnson; Verily’s Brian Otis; Openwater’s Mary Lou Jepsen; and Khosla Ventures’ Vinod Khosla


Neurosteer seeks pharmaceutical partners for clinical trial optimization, and health system/hospital partners for disease management and treatment studies.